The total number of records retrieved from this search are 35. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_927	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 virus particle/cell	In-vitro result70% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_928	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 virus particle/ cell	In-vitro result80% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_929	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 virus particle/ cell	In-vitro result80% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_930	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 virus particle/ cell	In-vitro resultAll cancer cell survive after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_959	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 virus particle/cell	In-vitro result90% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_960	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 virus particle/ cell	In-vitro result90% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_961	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 virus particle/ cell	In-vitro result60% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_962	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 virus particle/ cell	In-vitro result20% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_991	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result90% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_992	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result90% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_993	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result80% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_994	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result60% cell kills after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_995	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result90% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_996	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result50% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_997	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result20% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_998	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result100% cell kills after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_999	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result60% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1000	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result100% cell kills after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1001	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result100% cell kills after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1002	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result100% cell kills after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1003	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result10% cell kills after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1004	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result100% cell kills after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1005	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result100% cell kills after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1006	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result100% cell kills after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1772	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1773	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1774	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1775	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1776	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1777	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result22% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1778	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_4205	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapanese cancer research resource bank	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration1 MOI	In-vitro result1 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4210	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapanese cancer research resource bank	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration0.01 MOI	In-vitro result1 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4211	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapanese cancer research resource bank	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration0.1 MOI	In-vitro result1 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4212	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapanese cancer research resource bank	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-SH	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration1 MOI	In-vitro result1 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056